SMARCA4 and prostate carcinoma: In fact, prostate cancer cell lines treated with a DNA Methyl Transferase 1 (DNMT1) inhibitor exhibit increased ZNF185 expression.77 Indeed, deregulation of ZNF185 expression seems to be a recurring event in different human cancers, including prostate cancer, primary lung tumours, colon cancer and HNSCC.78,79 These data suggest a putative tumour suppressor function for ZNF185 by regulating cell proliferation and differentiation.80 Moreover, in lung cancer, BRG1, a component of the human switch/sucrose non-fermenting complex (SWI/SNF), regulates ZNF185 expression (Figure 4c).